Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DKPEI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
trastuzumab-Compound 30
|
|||||
| Synonyms |
trastuzumab-Compound 30
Click to Show/Hide
|
|||||
| Organization |
PHEON THERAPEUTICS LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-amido-PEG8-acid
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
1- (3- (2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)propanamido)-n- ((2s)-1- (( (2s)-1 (( (1s,9s)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,12,13,13a,14 octahydro-1h-benzo[de]pyrano[3',4':6,7]indeno[1,2-b]quinolin-1-yl)amino)-1 oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24 octaoxaheptacosan-27-amide
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 3.07 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
NCI-N87 (HER2+++)
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||